

9TH SYSTEMIC SCLEROSIS WORLD CONGRESS

SCIENTIFIC PROGRAMME

THURSDAY, MARCH 5

08:00

Registration opens

PRE-Congress Workshops

09:00-10:30 First slot pre-congress Workshops
10:30-11:00 Coffee break
11:00-12:30 Second slot pre-congress Workshops

PRE-Congress Workshop 1

FIBROTIC SKIN MANIFESTATIONS - NEW DIAGNOSTIC AND THERAPEUTIC APPROACHES

Convenor: **Thomas Krieg (Germany)**

PRE-Congress Workshop 2

DIGITAL ULCERS IN SSC - A COMPREHENSIVE APPROACH TO THE ASSESSMENT AND MANAGEMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS

Convenor: **Michael Hughes (UK)**

PRE-Congress Courses

08:30-13:30

PRE-Congress Course 1 - CAPILLAROSCOPY

Convenor: **Vanessa Smith (Belgium)**

08:30-12:30

PRE-Congress Course 2 - WSF/SCTC MRSS-TRAINING AND STANDARDIZATION

Convenor: **Dinesh Khanna (USA)**

13:45-14:45

SESSION 1 - LUNG

The view of the patient: **Ilaria Galetti (Italy)**

The view of the pulmonologist: **Vincent Cottin (France)**

The view of the rheumatologist: **Anna-Maria Hoffman-Vold (Norway)**

• 14:25-14:35

OC 01 - CONTEMPORARY TREATMENT PATTERNS AND CLINICAL DETERMINANTS OF THERAPYCHOICES IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: INSIGHTS FROM THE EUSTAR DATABASE - **Corrado Campochiaro et al (Italy)**

• 14:35-14:45

OC 02 - RISK FACTORS AND TRAJECTORIES OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS IN THE EUSTAR COHORT - **Antonio Tonutti et al (Italy)**

14:45-15:10

INVITED LECTURE 1

Bridging biology to clinical practice in PAH: future opportunities for SSC-PAH - **Katerina Antoniou (Greece)**

15:10-16:00

SESSION 2 - HEART

• 15:10-15:30

Unmasking and managing pH - **Giacomo De Luca (Italy)**

• 15:30-15:40

OC 03 - INITIAL THERAPY IN SSC-PAH IMPROVES OUTCOMES ACROSS HAEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION: INSIGHTS FROM THE EUSTAR DATABASE

Hilde Jenssen Bjørkekjær et al (Norway)

• 15:40-15:50

OC 04 - HIGH TYPE 1 INTERFERON ASSOCIATES WITH SUBCLINICAL MYOCARDIAL INVOLVEMENT IN SYSTEMIC SCLEROSIS

Cristiana Sieiro Santos et al (UK)

• 15:50-16:00

OC 05 - ARRHYTHMIC BURDEN, MYOCARDIAL MARKERS, AND LONG-TERM SURVIVAL IN DISTINCT CARDIAC MAGNETIC RESONANCE SUBSETS OF SYSTEMIC SCLEROSIS - **Davide Patti Gaspare et al (Italy)**



MARCH 5-7, 2026 ATHENS, GREECE

THURSDAY, MARCH 5

16:00-16:30
ASTRAZENECA SATELLITE SYMPOSIUM

16:30-17:30
MSD SATELLITE SYMPOSIUM

17:30-18:10
OPENING OF THE CONGRESS

18:10-19:10
OPENING LECTURES
• 18:10-18:30
Clinical - **Virginia Steen (USA)**

• 18:30-18:50
Basic - **Joerg Distler (Germany)**
• 18:50-19:10
Is it time to implement patient care through patient
Sue Farrington (UK)

19:10
WELCOME RECEPTION

FRIDAY, MARCH 6

07:30-08:30
MEET THE EXPERT SESSIONS
• How to evaluate circulation in SSc - **Michael Hughes (UK)**
• Myositis in SSc, so hidden so important - **Dan Furst (USA)**

08:00-09:00
SESSION 3 - IMAGING
• 08:00-08:20
Ultrasound of the Gastrointestinal SSc - **Giulia Bandini (Italy)**
• 08:20-08:40
Cardiac Magnetic Resonance in SSc
Sophie Mavrogeni (Greece)
• 08:40-08:50

OC 06 - ELEVATED MORTALITY LINKED TO MYOCARDIAL FIBROSIS IN SYSTEMIC SCLEROSIS: A MULTICENTER CMR STUDY IN AUTOIMMUNE RHEUMATIC DISEASES - **Attila Feher et al (USA)**

• 08:50-09:00
OC 07 - UNSUPERVISED CLUSTERING IDENTIFIES DISTINCT CMR DERIVED PHENOTYPES IN A COHORT OF SSC PATIENTS WITH LOW CARDIOVASCULAR RISK AND NO PRIOR CARDIAC
Mohammed Amr et al (UK)

09:00-10:00
SESSION 4 - VASCULAR
• 09:00-09:20
The complex world of Extracellular Vesicles as markers of vascular injury - **Jelena Colic (Serbia)**
• 09:20-09:30

OC 08 - UNMASKING LOWER LIMB PERIPHERAL ARTERIAL DISEASE IN SYSTEMIC SCLEROSIS THROUGH DOPPLER WAVEFORM ANALYSIS - **Begonya Alcacer-Pitarch et al (UK)**

• 09:30-09:40
OC 09 - RISK FACTORS OF PROGRESSION OF CALCINOSIS AND ACRO-OSTEOLYSIS IN THE HANDS OF PATIENTS WITH SYSTEMIC SCLEROSIS : A LONGITUDINAL OBSERVATIONAL STUDY
Alain Lescoat et al (France)

9TH SYSTEMIC SCLEROSIS WORLD CONGRESS

FRIDAY, MARCH 6

• 09:40-09:50

OC 10 - ASSOCIATION BETWEEN VASOACTIVE-VASODILATING THERAPY AND REDUCED DETECTION OF PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS: EVIDENCE FROM A EUSTAR STUDY

Cosimo Bruni (Switzerland)

• 09:50-10:00

OC 11 - POINTS TO CONSIDER FOR REPORTING OUTCOMES MEASURES IN SYSTEMIC SCLEROSIS INTERVENTIONAL STUDIES ON DIGITAL ULCERS: AN INITIATIVE FROM THE WORLD SCLERODERMA FOUNDATION DIGITAL ULCER AD HOC COMMITTEE

Corrado Campochiaro et al (Italy)

10:00-10:30 • COFFEE BREAK

10:30-11:50

SESSION 5 - VERY EARLY DISEASE AND PREVENTION OF DAMAGE IN IMMUNE MEDIATED DISEASES

• 10:30-10:40

Very Early Disease in SSc- what have we learnt so far
Francesco del Galdo (UK)

• 10:40-11:00

Delaying the onset of Type I Diabetes: a model and a new opportunity - **Ana Llego-Delgado (USA)**

• 11:00-11:20

The APPIPRA study in RA - **Kulveer Mankia (UK)**

• 11:20-11:30

OC 12 - EARLY PROGRESSION OF SYSTEMIC SCLEROSIS: A LONGITUDINAL COHORT STUDY ON DISEASE EVOLUTION AND MICROVASCULAR CHANGES

Dieneke Haverkort et al (The Netherlands)

• 11:30-11:40

OC 13 - MULTIMODAL IMAGING DIFFERENCES BETWEEN PRE-SYSTEMIC SCLEROSIS (PRE-SSC) PATIENTS VERSUS HEALTHY CONTROLS: A CROSS-SECTIONAL STUDY - **Ramona Govender et al (Belgium)**

• 11:40-11:50

OC 14 - SPATIAL TRANSCRIPTOMICS REVEALS DISTINCT AND OVERLAPPING PROFILES IN SPECIFIC SKIN REGIONS OF VERY EARLY SYSTEMIC SCLEROSIS

Ifeoluwa Emmanuel Bamigbola et al (UK)

11:50-13:20

BOEHRINGER INGELHEIM SATELLITE SYMPOSIUM

13:20-14:25 • POSTER TOUR AND LUNCH

14:25-15:25

BRISTOL-MYERS SQUIBB SATELLITE SYMPOSIUM

15:30-15:55

INVITED LECTURE 2

Fibroblasts in Inflammation and Fibrosis

George Kollias (Greece)

16.00-16:40

SESSION 6 - JOURNALS

• 16:00-16:10

JSRD

Attitudes and barriers to pulmonary arterial hypertension screening in SSc: A survey of UK-based rheumatologists

Louise Sander et al (Germany)

16:10-16:20

Rheumatology

Live course management of Systemic Sclerosis from Children to Adult. A prospective from the BSR Guidelines

Clare Pain et al (UK)

• 16:20-16:30

Nature Rheumatology

Perspective: An international perspective on the future of SSc research - **David Abraham et al (UK)**

• 16:30-16:40

Lancet Rheumatology

Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in SSc

John Pauling et al (UK)

16:40-17:10 • COFFEE BREAK



MARCH 5-7, 2026 ATHENS, GREECE

FRIDAY, MARCH 6

17:10-17:35

INVITED LECTURE 3

Antibodies, on the interface between SSc, myositis and cancer
Livia Casciola-Rosen (USA)

17:35-18:25

PARALLEL SESSION 7 - ENVIRONMENTAL FACTORS

• 17:35-17:55
Silica, an inducer of SSc? - **Alain Lescoat (France)**

• 17:55-18:15

Breast implants and SARDs - **Maria Grazia Lazzaroni (Italy)**

• 18:15-18:25

OC 15 - SYSTEMIC SCLEROSIS IN ISRAEL: A 20-YEAR NATIONWIDE STUDY OF PREVALENCE, HOT SPOTS AND SURVIVAL ANALYSIS
Doron Rimar et al (Israel)

18:25-19:05

PARALLEL SESSION 8 - JUVENILE VS ADULTS

Kathryn Torok (USA) vs Chris Denton (UK)

• 18:55-19:05

OC 16 - PULMONARY FUNCTION AND INTERSTITIAL LUNG DISEASE IN JUVENILE SYSTEMIC SCLEROSIS: INSIGHTS FROM THE LARGEST SINGLE-SITE PEDIATRIC SCLERODERMA REGISTRY

Kathryn Torok et al (USA)

17:10-19:10

PARALLEL SESSION 9 - BASIC (OMICS)

• 17:10-17:40
Novel insights from renal and cardiac fibrosis - implications for SSc
Christoph Kuppe (Germany)

• 17:40-18:10

Synovial Fibroblasts and their Interactions in the Rheumatoid Arthritis Tissue Microenvironment - **Kevi Wei (USA)**

• 18:10-18:20

OC 17 - SPATIAL PROTEOMIC-BASED PHENOTYPING OF FIBROBLAST POPULATIONS AND THEIR MICROENVIRONMENT IN SYSTEMIC SCLEROSIS PRIMARY HEART INVOLVEMENT

Andrea-Hermina Györfi et al (Germany)

• 18:20-18:30

OC 18 - SPATIAL PROFILING OF SCLERODERMA RENAL CRISIS REVEALS FIBROBLAST EXPANSION AND COMPLEMENT ACTIVATION
Minrui Liang et al (China)

• 18:30-18:40

OC 19 - MAPPING THE RNA METHYLOME IN SYSTEMIC SCLEROSIS: REGULATION AND ROLE IN TGF-B SIGNALING
Nikolaos Vlachogiannis et al (Greece)

• 18:40-18:50

OC 20 - ONE PROTEIN, MANY PATHS: MINDIN ORCHESTRATES SUBTYPE-SPECIFIC PROFIBROTIC FIBROBLAST RESPONSES IN SCLERODERMA
Gaurav Prafullbhai Kansagara et al (India)

• 18:50-19:00

OC 21 - MAPPING CELLULAR METABOLIC CHANGES IN SSC SKIN USING IMAGING MASS CYTOMETRY
Andrea Hermina Györfi et al (Germany)

• 19:00-19:10

OC 22 - MULTI-OMIC ANALYSIS IDENTIFIES A MONOCYTE-VASCULAR SIGNATURE LINKED TO SKIN FIBROSIS REGRESSION IN SYSTEMIC SCLEROSIS - **Astrid Hofman et al (Switzerland)**

SATURDAY, MARCH 7

07:30-08:30

MEET THE EXPERT SESSIONS

- How to manage a SRC - **Chris Denton (UK)**
- Vasculopathy, from pathogenesis to management
Marco Matucci-Cerinic (Italy)

(Reservations will open soon)

08:30-09:30

PARALLEL SESSION 10 - ORAL PRESENTATION CLINICAL

• 08:30-08:40

OC 23 - CALCINOSIS IN SYSTEMIC SCLEROSIS: FREQUENCY, CHARACTERISTICS AND ASSOCIATIONS IN AN AUSTRALIAN COHORT
Lauren Host et al (Australia)

• 08:40-08:50

OC 24 - REAL-WORLD EVIDENCE PREVALENCE AND CLINICAL OUTCOME OF PATIENTS MEETING THE INCLUSION CRITERIA OF THE PHASE 3 TRIAL DAISY (DETECTING EFFECTIVENESS OF ANIFROLUMAB IN SSC) - A EUSTAR COHORT STUDY - **Lesley Anne Bissell et al (UK)**

• 08:50-09:00

OC 25 - PREVALENCE OF ORGAN INVOLVEMENT AND BASELINE PREDICTORS OF DISEASE PROGRESSION IN PATIENTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: INSIGHTS FROM THE CONQUER DATABASE - **Alain Lescoat et al (France)**

• 09:00-09:10

OC 26 - WHICH ANTI-CENTROMERE ANTIBODY-POSITIVE SYSTEMIC SCLEROSIS PATIENTS ARE LESS LIKELY TO DEVELOP ORGAN INVOLVEMENT? INSIGHTS FROM THE EUSTAR COHORT
Jelena Colic et al (Serbia)

• 09:10-09:20

OC 27 - A HIGH-INTENSITY INTERVAL AND RESISTANCE TRAINING PROGRAMME IMPROVES PAIN AND FATIGUE OUTCOMES IN PEOPLE WITH SYSTEMIC SCLEROSIS: A EUROPEAN MULTI-CENTRE RANDOMISED CONTROLLED TRIAL - **Alexandros Mitropoulos et al (UK)**

• 09:20-09:30

OC 28 - CLINICAL CHARACTERISTICS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE IN MIXED CONNECTIVE TISSUE DISEASE AND SYSTEMIC SCLEROSIS: INSIGHTS FROM AN EMR-DERIVED COHORT

Alana Haussmann et al (USA)

08:30-09:30

PARALLELS SESSION 11 - (INFLAMMATORY CELLS/ PATHWAYS)

• 08:30-08:40

OC 29 - SKIN MACROPHAGE SUBTYPES AND IMPACT OF TOFACITINIB IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: RESULTS FROM COMBINED SINGLE-CELL ANALYSES OF AN OBSERVATIONAL DATA SET AND A PHASE I/II RANDOMIZED CONTROLLED TRIAL - **Alain Lescoat et al (France)**

• 08:40-08:50

OC 30 - ANTI-TOPOISOMERASE-1 AUTOANTIBODIES INDUCE TYPE I INTERFERON THROUGH THE CGAS-STING PATHWAY
Bent Deleuran et al (Denmark)

• 08:50-09:00

OC 31 - NK CELL IMMUNOTHERAPY REVERSES LUNG FIBROSIS BY ELIMINATING SENESCENT FIBROBLASTS
Wolfgang Merkt et al (Germany)

• 09:00-09:10

OC 32 - NOVEL MONOCYTE GENE SIGNATURES PREDICT PROGRESSION IN SYSTEMIC SCLEROSIS-ASSOCIATED ILD - **Cristina Padilla et al (USA)**

• 09:10-09:20

OC 33 - MONOCYTE-DERIVED MACROPHAGES IN SYSTEMIC SCLEROSIS: INTEGRATED SINGLE-CELL ANALYSIS ACROSS TISSUE COMPARTMENTS
Sandra Maribel Lopez Garces et al (UK)

• 09:20-09:30

OC 34 - IL-1- β AND MICROVASCULAR ENDOTHELIAL CELLS SYNERGIZE TO FAVOR ALTERED MACROPHAGE EFFEROCYTOSIS: IMPLICATION IN SSC - **Cécile Contin-Bordes et al (France)**



MARCH 5-7, 2026 ATHENS, GREECE

SATURDAY, MARCH 7

09:30-10:30

PARALLEL SESSION 12- ORAL PRESENTATION CLINICAL

• 09:30-09:40

OC 35 - FROM FIRST SYMPTOM TO DIAGNOSIS: INITIAL SYMPTOMS AND DELAYS IN SYSTEMIC SCLEROSIS FROM THE EARLY SYSTEMIC SCLEROSIS LONGITUDINAL ASSESSMENT REGISTRY

Aslihan Avanoglu Guler et al (Turkey)

• 09:40-09:50

OC 36 - PLATELETS' METABOLISM AND FUNCTIONS IN VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS AND IN ESTABLISHED DISEASE

Annalisa Villa et al (Italy)

• 09:50-10:00

OC 37 - EXTERNAL VALIDATION AND EXPLORATION OF CONCEPTUAL MODELS OF LATE SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS

Michael Hughes et al (UK)

• 10:00-10:10

OC 38 - COMPARING LONG-TERM OUTCOMES ACROSS SYSTEMIC SCLEROSIS SUBGROUPS USING A MULTI-ORGAN DISEASE PROGRESSION SCORE

Philip Yee et al (UK)

• 10:10-10:20

OC 39 - 68GA-FAPI PET/CT FOR TRACKING DISEASE TRAJECTORY IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE

Panagiotis Garantziotis et al (Germany)

• 10:20-10:30

OC 40 - MACHINE LEARNING-DRIVEN PHENOTYPING IN SYSTEMIC SCLEROSIS: CRP-DEFINED INFLAMMATION AND CLINICAL CLUSTERS - AN EUSTAR REGISTRY ANALYSIS

Cristiana Sieiro Santos et al (UK)

09:30-10:40

PARALLEL SESSION 13 - PRESENTATION BASIC III (HODGEPODGE)

• 09:30-09:40

OC 41 - FIBROTIC ECM-TARGETING EXTRACELLULAR VESICLES AS MEDIATORS OF SYSTEMIC PROGRESSION IN SYSTEMIC SCLEROSIS

Shally Tartakover Matalon et al (Israel)

• 09:40-09:50

OC 42 - CROSS-TRAIT GENETIC ANALYSIS REVEALS MEOX2 AS A NOVEL SUSCEPTIBILITY LOCUS SHARED BETWEEN PRIMARY RAYNAUD'S PHENOMENON AND SYSTEMIC SCLEROSIS

Carlos Rangel-Peláez et al (Spain)

• 09:50-10:00

OC 43 - PULMONARY ARTERIAL HYPERTENSION SUSCEPTIBILITY IN SYSTEMIC SCLEROSIS PATIENTS WITH THE DNASE1L3 RS35677470 (ARG206CYS) VARIANT

Brian Skaug et al (USA)

• 10:00-10:10

OC 44 - PROTEOMIC AND TRANSCRIPTOMIC ANALYSES ELUCIDATE THE TRAJECTORY OF PROGRESSION FROM THE ANTIBODY-POSITIVE PHASE TO THE DEVELOPMENT OF SSC

Fenglin Wu et al (China)

• 10:10-10:20

OC 45 - N-LACTOYL-AMINO ACIDS AS METABOLIC SIGNATURES OF FIBROTIC TRANSFORMATION IN SYSTEMIC SCLEROSIS SKIN: INSIGHTS FROM INTEGRATED METABOLOMIC AND TRANSCRIPTOMIC ANALYSIS

Amin Ravaei et al (Sweden)

• 10:20-10:30

OC 46 - MUC16 MUTATIONS ARE ASSOCIATED WITH GENOMIC INSTABILITY AND POOR OUTCOMES IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS

Mohammed Osman et al (Canada)

• 10:30-10:40

OC 47 - SPATIAL TRANSCRIPTOMIC-BASED PHENOTYPING OF THE FIBROBLAST NICHES IN SYSTEMIC SCLEROSIS-ASSOCIATED PRIMARY HEART INVOLVEMENT

Alexandru Micu et al (Germany)

10:30-11:00 • COFFEE BREAK

11:00-11:50

SESSION 14 - ORAL PRESENTATION ON GI

• 11:00-11:10

OC 48 - ASSOCIATION BETWEEN ESOPHAGEAL SYMPTOMS AND HIGH RESOLUTION MANOMETRY FINDINGS: ENHANCING MOTILITY ASSESSMENT WITH MULTIPLE SWALLOWING TESTS

Carlos Gomes et al (Portugal)

SATURDAY, MARCH 7

• 11:10-11:20

OC 49 - HIGH-DEFINITION SPATIAL TRANSCRIPTOMICS REVEALS DISTINCT IMMUNE, FIBROTIC, AND METABOLIC SIGNATURES IN EARLY AND LATE SYSTEMIC SCLEROSIS SMALL BOWEL DISEASE

Laura Much et al (Switzerland)

• 11:20-11:30

OC 50 - SEGMENTAL LOSS OF MOTILITY DRIVES REDUCED SMALL BOWEL FUNCTION IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: A PILOT MR ENTEROGRAPHY STUDY - **Marco Minerba et al (UK)**

• 11:30-11:40

OC 51 - APPLICABILITY AND DIAGNOSTIC VALUE OF CHICAGO CLASSIFICATION 4.0 IN ASSESSING ESOPHAGEAL MOTILITY DISORDERS IN SYSTEMIC SCLEROSIS: A RETROSPECTIVE SINGLE-CENTER STUDY

Carlos Gomes et al (Portugal)

• 11:40-11:50

OC 52 - DELAYED GASTRIC EMPTYING IDENTIFIES A HIGH-RISK CLINICAL SUBGROUP IN PATIENTS WITH SYSTEMIC SCLEROSIS

Francisco Alejandro Felix-Tellex et al (Spain)

11:50-12:35

BOEHRINGER INGELHEIM ROUND TABLE

12:35-13:50 • POSTER TOUR AND LUNCH

13:50-14:20

ARGENX SATELLITE SYMPOSIUM

14:20-14:45

INVITED LECTURE 4

Activity and damage

Mandana Nikpour (Australia)

14:45-16:45

SESSION 15 THERAPY

• 14:45-15:05

Evidence to support combination therapies in SSc

Yannick Allanore (France)

• 15:05-15:25

New molecular targets in SSc- current and ongoing trials.

Dinesh Khanna (USA)

• 15:25-15:35

OC 53 - TARGETING THE PLASMA CELL NICHE IN SYSTEMIC SCLEROSIS: A CASE SERIES ABOUT THE BISPECIFIC ANTI-BCMAXCD3 ANTIBODY TECLISTAMAB IN SEVERE, TREATMENT-REFRACTORY PATIENTS

Andrea Hermina et all (Germany)

• 15:35-15:45

OC 54 - USE OF THE CD19/CD3 T CELL ENGAGER BLINATUMOMAB IN REFRACTORY SYSTEMIC SCLEROSIS: A CASE SERIES

Jerome Avouac et al (France)

• 15:45-15:55

OC 55 - TIMING MATTERS: EARLY AUTOLOGOUS STEM CELL TRANSPLANTATION SHOWS A LOWER MORTALITY IN HIGH-RISK DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS - PRELIMINARY RESULTS FROM THE UPSIDE TRIAL - **Julia Spierings et al (The Netherlands)**

• 15:55-16:05

OC 56 - RECONNOITER-1: A PHASE 2, PROSPECTIVE, BLINDED, RANDOMIZED, PARALLEL-GROUP AND CROSSOVER CLINICAL TRIAL EVALUATING AISA-021, A NOVEL CCB, IN SUBJECTS WITH RAYNAUD'S PHENOMENON (SSC-RP) (PRESENTER FROM UNITED KINGDOM) - **Francesco Del Galdo et al (USA)**

CART CELL THERAPIES:

• 16:05-16:25

CarT cell therapy, where are we now, opportunities and risks

Sasha Dietrich (Germany)

• 16:25-16:35

OC 57 - SAFETY AND EARLY EFFICACY OF RAPCABTAGENE AUTOLEUCEL, AN AUTOLOGOUS CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN SEVERE REFRACTORY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS - **Dinesh Khanna et al (USA)**

• 16:35-16:45

OC 58 - SAFETY AND EFFICACY OF CD19 NEX-T® (BMS-986353), A CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN SYSTEMIC SCLEROSIS (SSc): FINDINGS FROM THE BREAKFREE-1 TRIAL

Dinesh Khanna et al (USA)

16:45-17:00

WRAP UP LECTURE

Zsuzsanna McMahan (USA) & Ulf Mueller-Ladner (Germany)

17:00

CLOSING REMARKS